The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications

Journal of Medicinal Chemistry

Volumn 48, Issue 16, 2005, Pages 5059-5087

  Lambert, Didier M ^a   Fowler, Christopher J ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 2 METHYL 3 (2 MORPHOLINOETHYL) 5 METHOXYINDOLE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; AM 1172; AM 411; AMIDE; ANANDAMIDE; ARACHIDONOYLGLYCINE; BAY 387271; BAY 593074; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOL; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DELTA8 TETRAHYDROCANNABINOL; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; GW 405833; METHANANDAMIDE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N OLEOYLETHANOLAMINE; O 1812; O 2654; PALMIDROL; RIMONABANT; SEP 0200228; SRI 41716A; STEAROYLETHANOLAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRODHAMINE;

ANIMAL CELL; BINDING AFFINITY; DRUG BINDING SITE; DRUG ISOLATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR UPREGULATION; REVIEW;

AMIDES; AMIDOHYDROLASES; AMINES; ANIMALS; ARACHIDONIC ACIDS; BINDING SITES; DRUG DESIGN; ENDOCANNABINOIDS; ESTERS; ETHERS; GLYCERIDES; HUMANS; LIGANDS; MONOACYLGLYCEROL LIPASES; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID;

EID: 23444432920     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058183t     Document Type: Review

References (430)

1. Lambert, D. M. Les Vertus Du Cannabis à Travers Les Millénaires (The Virtues of Cannabis through the Millenium). J. Pharm. Belg. 2001, 56, 111-118.
2. Adams, I. B.; Martin, B. R. Cannabis: Pharmacology and Toxicology in Animals and Humans. Addiction 1996, 91, 1585-1614.
3. Zias, J.; Stark, H.; Seligman, J.; Levy, R.; Werker, E.; Breuer, A.; Mechoulam, R. Early Medical Use of Cannabis. Nature 1993, 363, 215.
4. Reynolds, J. R. R. On the Therapeutical Uses and Toxic Effects of Cannabis Indica. Lancet 1890, 135, 637-638.
5. Adams, R.; Hunt, M.; Clark, J. H. Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I. J. Am. Chem. Soc. 1940, 62, 196-200.
6. Adams, R.; Baker, B. R.; Wearn, R. B. Structure of Cannabinol. III. Synthesis of Cannabinol, 1-Hydroxy-3-n-amyl-6,6,9-trimethyl-6-dibenzopyran. J. Am. Chem. Soc. 1940, 62, 2204-2207.
7. Mechoulam, R.; Shvo, Y. Hashish-I: The Structure of Cannabidiol. Tetrahedron 1963, 19, 2073-2078.
8. Gaoni, Y.; Mechoulam, R. Isolation, Structure and Partial Synthesis of an Active Constituent of Hashish. J. Am. Chem. Soc. 1964, 86, 1646-1647.
9. 1-Tetrahydrocannabinol, the Major Active Constituent of Hashish. Tetrahedron Lett. 1967, 8, 1109-1111.
10. Mechoulam, R.; Hanus, L. A Historical Overview of Chemical Research on Cannabinoids. Chem. Phys. Lipids 2000, 108, 1-13.
11. Mechoulam, R. Looking Back at Cannabis Research. Curr. Pharm. Des. 2000, 6, 1313-1322.
12. Offertaler, L.; Mo, F. M.; Batkai, S.; Liu, J.; Begg, M.; Razdan, R. K.; Martin, B. R.; Bukoski, R. D.; Kunos, G. Selective Ligands and Cellular Effectors of a G Protein-Coupled Endothelial Cannabinoid Receptor. Mol. Pharmacol. 2003, 63, 699-705.
13. Mechoulam, R.; Hanus, L. Cannabidiol: An Overview of Some Chemical and Pharmacological Aspects. Part I: Chemical Aspects. Chem. Phys. Lipids 2002, 121, 35-43.
14. Walton, R. P.; Martin, L. F.; Keller, J. H. The Relative Activity of Various Purified Products Obtained from American Grown Hashish. J. Pharmacol. Exp. Ther. 1938, 62, 239-251.
15. Edery, H.; Grunfeld, Y.; Ben-Zvi, Z.; Mechoulam, R. Structural Requirements for Cannabinoid Activity. Ann. N. Y. Acad. Sci. 1971, 191, 40-53.
16. Razdan, R. K. Structure-Activity Relationships in Cannabinoids. Pharmacol. Rev. 1986, 38, 75-149.
17. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol. Rev. 2002, 54, 161-202.
18. Martin, B. Cellular Effects of Cannabinoids. Pharmacol. Rev. 1986, 38, 45-74.
19. Howlett, A. Inhibition of Neuroblastoma Adenylate Cyclase by Cannabinoid and Nantradol Compounds. Life Sci. 1984, 35, 1803-1810.
20. Howlett, A. Cannabinoid Inhibition of Adenylate Cyclase. Biochemistry of the Response in Neuroblastoma Cell Membranes. Mol. Pharmacol. 1985, 27, 429-436.
21. Howlett, A.; Qualy, J.; Khachatrian, L. Involvement of Gi in the Inhibition of Adenylate Cyclase by Cannabimimetic Drugs. Mol. Pharmacol. 1986, 29, 307-313.
22. Devane, W. A.; Dysarz, F. A.; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. Determination and Characterization of a Cannabinoid Receptor in Rat Brain. Mol. Pharmacol. 1988, 34, 605-613.
23. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA. Nature 1990, 346, 561-564.
24. Munro, S.; Thomas, K. L.; Abu, S. M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 1993, 365, 61-65.
25. Ford, W. R.; Honan, S. A.; White, R.; Hiley, C. R. Evidence of a Novel Site Mediating Anandamide-Induced Negative Inotropic and Coronary Vasodilatator Responses in Rat Isolated Hearts. Br. J. Pharmacol. 2002, 135, 1191-1198.
26. 1 Receptor-Independent Action. Eur. J. Neurosci. 2003, 18, 1973-1978.
27. 1-Mediated Actions. Neuropharmacology 2004, 46, 115-125.
28. 2 Receptors. Proc. Natl. Acad. Sci. U.S.A 1999, 96, 14136-14141.
29. Mechoulam, R.; Ben Shabat, S. From Gan-Zi-Gun-Nu to Anandamide and 2-Arachidonoylglycerol: The Ongoing Story of Cannabis. Nat. Prod. Rep. 1999, 16, 131-143.
30. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science 1992, 258, 1946-1949.
31. Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Martin, B. R. Cannabimimetic Fatty Acid Derivatives: The Anandamide Family and Other Endocannabinoids. Curr. Med. Chem. 1999, 6, 721-744.
32. van der Stelt, M.; Di Marzo, V. Endovanilloids-Putative Endogenous Ligands of Transient Receptor Potential Vanilloid 1 Channels. Eur. J. Biochem. 2004, 271, 1827-1834.
33. Shire, D.; Carillon, C.; Kaghad, M.; Calandra, B.; Rinaldi, C. M.; Le Fur, G.; Caput, D.; Ferrara, P. An Amino-Terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing. J. Biol. Chem. 1995, 270, 3726-3731.
34. [Erratum appears in J. Biol. Chem. 1996, 271, 33706].
35. 1 Receptor. FEBS Lett. 2005, 579, 259-264.
36. Mackie, K.; Devane, W. A.; Hille, B. Anandamide, an Endogenous Cannabinoid, Inhibits Calcium Currents as a Partial Agonist in N18 Neuroblastoma Cells. Mol. Pharmacol. 1993, 44, 498-503.
37. Vogel, Z.; Barg, J.; Levy, R.; Saya, D.; Heldman, E.; Mechoulam, R. Anandamide, a Brain Endogenous Compound, Interacts Specifically with Cannabinoid Receptors and Inhibits Adenylate-Cyclase. J. Neurochem. 1993, 61, 352-355.
38. Kenakin, T. Agonist-Receptor Efficacy II: Agonist Trafficking of Receptor Signals. Trends Pharmacol. Sci. 1995, 16, 232-238.
39. Berg, K. A.; Maayani, S.; Goldfarb, J.; Scaramelli, C.; Leff, P.; Clarke, W. P. Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus. Mol. Pharmacol. 1998, 54, 94-104.
40. i Protein Interactions. Mol. Pharmacol. 2005, 67, 2016-2024.
41. Fride, E.; Mechoulam, R. Pharmacological Activity of the Cannabinoid Receptor Agonist, Anandamide, a Brain Constituent. Eur. J. Pharmacol. 1993, 231, 313-314.
42. Pertwee, R. G. Cannabinoid Receptors and Pain. Prog. Neurobiol. 2001, 63, 569-611.
43. Rice, A. S. C.; Farquhar-Smith, W. P.; Nagy, I. Endocannabinoids and Pain: Spinal and Peripheral Analgesia in Inflammation and Neuropathy. Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66, 243-256.
44. Ross, R. A. Anandamide and Vanilloid TRPV1 Receptors. Br. J. Pharmacol. 2003, 140, 790-801.
45. Ahluwalia, J.; Mohammed, Y.; Laszlo, U.; Stuart, B.; Istvan, N. Activation of Capsaicin-Sensitive Primary Sensory Neurones Induces Anandamide Production and Release. J. Neurochem. 2003, 84, 585-591.
46. 2 Receptor Agonist Palmitoylethanolamide in Visceral and Somatic Inflammatory Pain. Pain 1998, 76, 189-199.
47. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of Pain Initiation by Endogenous Cannabinoids. Nature 1998, 394, 277-281.
48. Vivian, J. A.; Kishioka, S.; Butelman, E. R.; Broadbear, J.; Lee, K. O.; Woods, J. H. Analgesic, Respiratory and Heart Rate Effects of Cannabinoid and Opioid Agonists in Rhesus Monkeys: Antagonist Effects of SR 141716A. J. Pharmacol. Exp. Ther. 1998, 286, 697-703.
49. 9-Tetrahydrocannabinol and Anandamide Antinociception in Nonarthritic and Arthritic Rats. Pharmacol. Biochem. Behav. 1998, 60, 183-191.
50. Richardson, J. D.; Aanonsen, L.; Hargreaves, K. M. Antihyperalgesic Effects of Spinal Cannabinoids. Eur. J. Pharmacol. 1998, 345, 145-153.
51. 1 Receptors. Pain 1998, 75, 111-119.
52. Maccarrone, M.; Finazzi-Agrò, A. The Endocannabinoid System, Anandamide and the Regulation of Mammalian Cell Apoptosis. Cell Death Differ. 2003, 10, 946-955.
53. Parolaro, D.; Massi, P.; Rubino, T.; Monti, E. Endocannabinoids in the Immune System and Cancer. Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66, 319-332.
54. Maccarrone, M.; Lorenzon, T.; Bari, M.; Melino, G.; Finazzi-Agrò, A. Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors. Evidence for a Protective Role of Cannabinoid Receptors. J. Biol. Chem. 2000, 275, 31938-31945.
55. Sarker, K. P.; Obara, S.; Nakata, M.; Kitajima, I.; Maruyama, I. Anandamide Induces Apoptosis of PC-12 Cells: Involvement of Superoxide and Caspase-3. FEBS Lett. 2000, 472, 39-44.
56. Mimeault, M.; Pommery, N.; Wattez, N.; Bailly, C.; Henichart, J. P. Anti-Proliferative and Apoptotic Effects of Anandamide in Human Prostatic Cancer Cell Lines: Implication of Epidermal Growth Factor Receptor Down-Regulation and Ceramide Production. Prostate 2003, 56, 1-12.
57. Yamaji, K.; Sarker, K. P.; Kawahara, K.; Iino, S.; Yamakuchi, M.; Abeyama, K.; Hashiguchi, T.; Maruyama, I. Anandamide Induces Apoptosis in Human Endothelial Cells: Its Regulation System and Clinical Implications. Thromb. Haemostasis 2003, 89, 875-884.
58. Ligresti, A.; Bisogno, T.; Matias, I.; De Petrocellis, L.; Cascio, M. G.; Cosenza, V.; D'Argenio, G.; Scaglione, G.; Bifulco, M.; Sorrentini, I.; Di Marzo, V. Possible Endocannabinoid Control of Colorectal Cancer Growth. Gastroenterology 2003, 125, 677-687.
59. Melck, D.; Rueda, D.; Galve-Roberh, I.; De Petrocellis, L.; Guzmán, M.; Di, M. V. Involvement of the cAMP/Protein Kinase A Pathway and of Mitogen-Activated Protein Kinase in the Anti-Proliferative Effects of Anandamide in Human Breast Cancer Cells. FEBS Lett. 1999, 463, 235-240.
60. Fowler, C. J.; Jonsson, K.-O.; Andersson, A.; Juntunen, J.; Jarvinen, T.; Vandevoorde, S.; Lambert, D. M.; Jerman, J. C.; Smart, D. Inhibition of C6 Glioma Cell Proliferation by Anandamide, 1-Arachidonoylglycerol, and by a Water Soluble Phosphate Ester of Anandamide: Variability in Response and Involvement of Arachidonic Acid. Biochem. Pharmacol. 2003, 66, 757-767.
61. Paria, B. C.; Ma, W.; Andrenyak, D. M.; Schmid, P. C.; Schmid, H. H. O.; Moody, D. E.; Deng, H.; Makriyannis, A.; Dey, S. K. Effects of Cannabinoids on Preimplantation Mouse Embryo Development and Implantation Are Mediated by Brain-Type Cannabinoid Receptors. Biol. Reprod. 1998, 58, 1490-1495.
62. Habayeb, O. M. H.; Bell, S. C.; Konje, J. C. Endogenous Cannabinoids: Metabolism and Their Role in Reproduction. Life Sci. 2002, 70, 1963-1977.
63. 9-Tetrahydrocannabinol or Anandamide. Psychopharmacology 1998, 140, 11-19.
64. Di Carlo, G.; Izzo, A. A. Cannabinoids for Gastrointestinal Diseases: Potential Therapeutic Applications. Expert Opin. Invest. Drugs 2003, 12, 39-49.
65. Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of Anxiety through Blockade of Anandamide Hydrolysis. Nat. Med. 2003, 9, 76-81.
66. Costa, B.; Parolaro, D.; Colleoni, M. Chronic Treatment with the Endocannabinoid Anandamide Increases Cytochrome P450 Metabolizing System in the Rat. Eur. J. Pharmacol. 2002, 449, 61-69.
67. Wallace, M. J.; Martin, B. R.; DeLorenzo, R. J. Evidence for a Physiological Role of Endocannabinoids in the Modulation of Seizure Threshold and Severity. Eur. J. Pharmacol. 2002, 452, 295-301.
68. 1 Cannabinoid Receptor-Dependent Modulation of Feeding. J. Neurosci. 2002, 22, 9612-9617.
69. Schmid, H. H. O.; Schmid, P. C.; Natarajan, V. N-Acylated Glycerophospholipids and Their Derivatives. Prog. Lipid Res. 1990, 29, 1-43.
70. Schmid, H. H. O.; Berdyshev, E. V. Cannabinoid Receptor-Inactive N-Acylethanolamines and Other Fatty Acid Amides: Metabolism and Function. Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66, 363-376.
71. Patricelli, M. P.; Cravatt, B. F. Proteins Regulating the Biosynthesis and Inactivation of Neuromodulatory Fatty Acid Amides. Vitam. Horm. 2001, 62, 95-131.
72. Deutsch, D. G.; Chin, S. A. Enzymatic Synthesis and Degradation of Anandamide, a Cannabinoid Receptor Agonist. Biochem. Pharmacol. 1993, 46, 791-796.
73. Ueda, N.; Kurahashi, Y.; Yamamoto, S.; Tokunaga, T. Partial Purification and Characterization of the Porcine Brain Enzyme Hydrolyzing and Synthesizing Anandamide. J. Biol. Chem. 1995, 270, 23823-23827.
74. Schmid, P. C.; Zuzarte-Augustin, M. L.; Schmid, H. H. O. Properties of Rat Liver N-Acylethanolamine Amidohydrolase. J. Biol. Chem. 1985, 260, 14145-14149.
75. Schmid, P. C.; Reddy, P. V.; Natarajan, V.; Schmid, H. H. O. Metabolism of N-Acylethanolamine Phospholipids by a Mammalian Phosphodiesterase of the Phospholipase D Type. J. Biol. Chem. 1983, 258, 9302-9306.
76. Ueda, N.; Liu, Q.; Yamanaka, K. Marked Activation of the N-Acylphosphatidylethanolamine-Hydrolyzing Phosphodiesterase by Divalent Cations. Biochim. Biophys. Acta 2001, 1532, 121-127.
77. Liu, Q.; Tonai, T.; Ueda, N. Activation of N-Acylethanolamine-Releasing Phospholipase D by Polyamines. Chem. Phys. Lipids 2002, 115, 77-84.
78. Okamoto, Y.; Morishita, J.; Tsuboi, K.; Tonai, T.; Ueda, N. Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners. J. Biol. Chem. 2004, 279, 5298-5305.
79. 2 and Lysophospholipase D. Biochem. J. 2004, 380, 749-756.
80. Hanus, L.; Gopher, A.; Almog, S.; Mechoulam, R. Two New Unsaturated Fatty Acid Ethanolamides in Brain That Bind to the Cannabinoid Receptor. J. Med. Chem. 1993, 36, 3032-3034.
81. Pertwee, R. G.; Griffin, G.; Lainton, J. A.; Huffman, J. W. Pharmacological Characterization of Three Novel Cannabinoid Receptor Agonists in the Mouse Isolated Vas Deferens. Eur. J. Pharmacol. 1995, 284, 241-247.
82. Barg, J.; Fride, E.; Hanus, L.; Levy, R.; Matus, L. N.; Heldman, E.; Bayewitch, M.; Mechoulam, R.; Vogel, Z. Cannabinomimetic Behavioral Effects of and Adenylate Cyclase Inhibition by Two New Endogenous Anandamides. Eur. J. Pharmacol. 1995, 287, 145-152.
83. Felder, C. C.; Briley, E. M.; Axelrod, J.; Simpson, J. T.; Mackie, K.; Devane, W. A. Anandamide, an Endogenous Cannabimimetic Eicosanoid, Binds to the Cloned Human Cannabinoid Receptor and Stimulates Receptor-Mediated Signal Transduction. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 7656-7660.
84. Walter, L.; Franklin, A.; Witting, A.; Moller, T.; Stella, N. Astrocytes in Culture Produce Anandamide and Other Acylethanolamides. J. Biol. Chem. 2002, 277, 20869-20876.
85. Walter, L.; Franklin, A.; Witting, A.; Wade, C.; Xie, Y.; Kunos, G.; Mackie, K.; Stella, N. Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration. J. Neurosci. 2003, 23, 1398-1405.
86. Lambert, D. M.; Di Marzo, V. The Palmitoylethanolamide and Oleamide Enigmas: Are These Two Fatty Acid Amides Cannabimimetic? Curr. Med. Chem. 1999, 6, 757-773.
87. 1 Cannabinoid Receptors. Br. J. Pharmacol. 2004, 141, 253-262.
88. Fowler, C. J. Oleamide: A Member of the Endocannabinoid Family? Br. J. Pharmacol. 2004, 141, 195-196.
89. Boger, D. L.; Henriksen, S. J.; Cravatt, B. F. Oleamide: An Endogenous Sleep-Inducing Lipid and Prototypical Member of a New Class of Biological Signaling Molecules. Curr. Pharm. Des. 1998, 4, 303-314.
90. Dougalis, A.; Lees, G.; Ganellin, C. R. The Sleep Lipid Oleamide May Represent an Endogenous Anticonvulsant: An in Vitro Comparative Study in the 4-Aminopyridine Rat Brain-Slice Model. Neuropharmacology 2004, 46, 541-554.
91. Martinez-Gonzalez, D.; Bonilla-Jaime, H.; Morales-Otal, A.; Henriksen, S. J.; Velazquez-Moctezuma, J.; Prospero-Garcia, O. Oleamide and Anandamide Effects on Food Intake and Sexual Behavior of Rats. Neurosci. Lett. 2004, 364, 1-6.
92. 1 Cannabinoid-Receptor Ligands and Inhibitors of Anandamide Inactivation with Cannabimimetic Activity in Vitro and in Vivo. Biochem. J. 2000, 351, 817-824.
93. Huang, S. M.; Bisogno, T.; Petros, T. J.; Chang, S. Y.; Zavitsanos, P. A.; Zipkin, R. E.; Sivakumar, R.; Coop, A.; Maeda, D. Y.; De Petrocellis, L.; Burstein, S.; Di Marzo, V.; Walker, J. M. Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain. J. Biol. Chem. 2001, 276, 42639-42644.
94. De Petrocellis, L.; Cascio, M. G.; Di Marzo, V. The Endocannabinoid System: A General View and Latest Additions. Br. J. Pharmacol. 2004, 141, 765-774.
95. Prescott, S. M.; Majerus, P. W. Characterization of 1,2-Diacylglycerol Hydrolysis in Human Platelets. Demonstration of an Arachidonoyl-Monoacylglycerol Intermediate. J. Biol. Chem. 1983, 258, 764-769.
96. Mechoulam, R.; Ben Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; Pertwee, R. G.; Griffin G.; Bayewitch, M.; Barg, J.; Vogelf, Z. Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors. Biochem. Pharmacol. 1995, 50, 83-90.
97. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97.
98. Stella, N.; Schweitzer, P.; Piomelli, D. A Second Endogenous Cannabinoid That Modulates Long-Term Potentiation. Nature 1997, 388, 773-778.
99. Ghafouri, N.; Tiger, G.; Razdan, R. K.; Mahadevan, A.; Pertwee, R. G.; Martin, B. R.; Fowler, C. J. Inhibition of Monoacylglycerol Lipase and Fatty Acid Amide Hydrolase by Analogues of 2-Arachidonoylglycerol. Br. J. Pharmacol. 2004,143, 774-784.
100. Rouzer, C. A.; Ghebreselasie, K.; Marnett, L. J. Chemical Stability of 2-Arachidonylglycerol under Biological Conditions. Chem. Phys. Lipids 2002, 119, 69-82.
101. 1 Receptor-Dependent G-Protein Activation in Rat Cerebellar Membranes. Br. J. Pharmacol. 2001, 134, 664-672.
102. 2 Receptor-Comparison of the Agonistic Activities of Various Cannabinoid Receptor Ligands in HL-60 Cells. J. Biol. Chem. 2000, 275, 605-612.
103. Melck, D.; De Petrocellis, L.; Orlando, P.; Bisogno, T.; Laezza, C.; Bifulco, M.; Di Marzo, V. Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation. Endocrinology 2000, 141, 118-126.
104. Járai, Z.; Wagner, J. A.; Goparaju, S. K.; Wang, L.; Razdan, R. K; Sugiura, T.; Zimmer, A. M.; Bonner, T. I.; Zimmer, A.; Kunos, G. Cardiovascular Effects of 2-Arachidonoyl Glycerol in Anesthetized Mice. Hypertension 2000, 35, 679-684.
105. Kojima, S. I.; Sugiura, T.; Waku, K.; Kamikawa, Y. Contractile Response to a Cannabimimetic Eicosanoid, 2-Arachidonoylglycerol, of Longitudinal Smooth Muscle from the Guinea-Pig Distal Colon in Vitro. Eur. J. Pharmacol. 2002, 444, 203-207.
106. Panikashvili, D.; Simeonidou, C.; Ben Shabat, S.; Hanus, L.; Breuer, A.; Mechoulam, R.; Shohami, E. An Endogenous Cannabinoid (2-AG) Is Neuroprotective after Brain Injury. Nature 2001, 413, 527-531.
107. Yamaguchi, T.; Hagiwara, Y.; Tanaka, H.; Sugiura, T.; Waku, K.; Shoyama, Y.; Watanabe, S.; Yamamoto, T. Endogenous Cannabinoid, 2-Arachidonoylglycerol, Attenuates Naloxone-Precipitated Withdrawal Signs in Morphine-Dependent Mice. Brain Res. 2001, 909, 121-126.
108. Stefano, G. B.; Bilfinger, T. V.; Rialas, C. M.; Deutsch, D. G. 2-Arachidonyl-Glycerol Stimulates Nitric Oxide Release from Human Immune and Vascular Tissues and Invertebrate Immunocytes by Cannabinoid Receptor 1. Pharmacol. Res. 2000, 42, 317-322.
109. Kishimoto, S.; Kobayashi, Y.; Oka, S.; Gokoh, M.; Waku, K.; Sugiura, T. 2-Arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, Induces Accelerated Production of Chemokines in HL-60 Cells. J. Biochem. (Tokyo) 2004, 135, 517-524.
110. Kirkham, T. C.; Williams, C. M.; Fezza, F.; Di Marzo, V. Endocannabinoid Levels in Rat Limbic Forebrain and Hypothalamus in Relation to Fasting, Feeding and Satiation: Stimulation of Eating by 2-Arachidonoyl Glycerol. Br. J. Pharmacol. 2002, 136, 550-557.
111. Piomelli, D. The Molecular Logic of Endocannabinoid Signalling. Nat. Rev. Neurosci. 2003, 4, 873-884.
112. Bisogno, T.; Howell, F.; Williams, G.; Minassi, A.; Cascio, M. G.; Ligresti, A.; Matias, I.; Schiano-Moriello, A.; Paul, P.; Williams, E. J.; Gangadharan, U.; Hobbs, C.; Di Marzo, V.; Doherty, P. Cloning of the First SnI-DAG Lipases Points to the Spatial and Temporal Regulation of Endocannabinoid Signaling in the Brain. J. Cell Biol. 2003, 163, 463-468.
113. Kreitzer, A. C.; Regehr, W. G. Retrograde Inhibition of Presynaptic Calcium Influx by Endogenous Cannabinoids at Excitatory Synapses onto Purkinje cells. Neuron 2001, 29, 717-727.
114. Ohno-Shosaku, T.; Maejima, T.; Kano, M. Endogenous Cannabinoids Mediate Retrograde Signals from Depolarized Postsynaptic Neurons to Presynaptic Terminals. Neuron 2001,29, 729-738.
115. Wilson, R. I.; Nicoll, R. A. Endogenous Cannabinoids Mediate Retrograde Signalling at Hippocampal Synapses. Nature 2001, 410, 588-592.
116. Diana, M. A.; Marty, A. Endocannabinoid-Mediated Short-Term Synaptic Plasticity: Depolarization-Induced Suppression of Inhibition (DSI) and Depolarization-Induced Suppression of Excitation (DSE). Br. J. Pharmacol. 2004, 42, 9-19.
117. 2+ Dependency for Triggering Retrograde Endocannabinoid Signal. Neuron 2005, 45, 257-268.
118. Melis, M.; Perra, S.; Muntoni, A. L.; Pillolla, G.; Lutz, B.; Marsicano, G.; Di Marzo, V.; Gessa, G. L.; Pistis, M. Prefrontal Cortex Stimulation Induced 2-Arachidonoyl-glycerol- Mediated Suppression of Excitation in Dopamine Neurons. J. Neurosci. 2004, 24, 10707-10715.
119. Azad, S. C.; Monory, K.; Marsicano, G.; Cravatt, B. F.; Lutz, B.; Zieglgänsberger, W.; Rammes, G. Circuitry for Associative Plasticity in the Amygdala Involves Endocannabinoid Signaling. J. Neurosci. 2004, 24, 9953-9961.
120. 1 Receptor. J. Pharmacol. Exp. Ther. 2002, 301, 1020-1024.
121. Markey, S. P.; Dudding, T.; Wang, T. C. Base- and Acid-Catalyzed Interconversions of O-Acyl and N-Acyl Ethanolamines: A Cautionary Note for Lipid Analyses. J. Lipid Res. 2000, 41, 657-662.
122. Ho, W. S. V.; Hiley, C. R. Vasorelaxant Activities of the Putative Endocannabinoid Virodhamine in Rat Isolated Small Mesenteric Artery. J. Pharm. Pharmacol. 2004, 56, 869-875.
123. 1 Receptor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3662-3665.
124. Milton, N. G. N. Anandamide and Noladin Ether Prevent Neurotoxicity of the Human Amyloid-β Peptide. Neurosci. Lett. 2002, 332, 127-130.
125. Fezza, F.; Bisogno, T.; Minassi, A.; Appendino, G.; Mechoulam, R.; Di Marzo, V. Noladin Ether, a Putative Novel Endocannabinoid: Inactivation Mechanisms and a Sensitive Method for Its Quantification in Rat Tissues. FEBS Lett. 2002, 513, 294-298.
126. Oka, S.; Tsuchie, A.; Tokumura, A.; Muramatsu, M.; Suhara, Y.; Takayama, H.; Waku, K.; Sugiura, T. Ether-Linked Analogue of 2-Arachidonoylglycerol (Noladin Ether) Was Not Detected in the Brains of Various Mammalian Species. J. Neurochem. 2003, 85, 1374-1381.
127. Laine, K.; Järvinen, K.; Mechoulam, R.; Breuer, A.; Järvinen, T. Comparison of the Enzymatic Stability and Intraocular Pressure Effects of 2-Arachidonylglycerol and Noladin Ether, a Novel Putative Endocannabinoid. Invest. Ophthalmol. Visual Sci. 2002, 43, 3216-3222.
128. 1 Receptors. Bioorg. Med. Chem. Lett. 2003,13, 43-46.
129. 2 Gi/o Linked Receptor. Br. J. Pharmacol. 2004, 142, 509-518.
130. Ben Shabat, S.; Fride, E.; Sheskin, T.; Tamiri, T.; Rhee, M. H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di, M. V.; Mechoulam, R. An Entourage Effect: Inactive Endogenous Fatty Acid Glycerol Esters Enhance 2-Arachidonoyl-Glycerol Cannabinoid Activity. Eur. J. Pharmacol. 1998, 353, 23-31.
131. De Petrocellis, L.; Davis, J. B.; Di Marzo, V. Palmitoylethanolamide Enhances Anandamide Stimulation of Human Vanilloid VRi Receptors. FEBS Lett. 2001, 506, 253-256.
132. Smart, D.; Jonsson, K. O.; Vandevoorde, S.; Lambert, D. M.; Fowler, C. J. "Entourage" Effects of N-Acyl Ethanolamines at Human Vanilloid Receptors. Comparison of Effects upon Anandamide-Induced Vanilloid Receptor Activation and upon Anandamide Metabolism. Br. J. Pharmacol. 2002, 136, 452-458.
133. Schmid, P. C.; Krebsbach, R. J.; Perry, S. R.; Dettmer, T. M.; Maasson, J. L.; Schmid, H. H. O. Occurrence and Postmortem Generation of Anandamide and Other Long-Chain N-Acylethanolamines in Mammalian Brain. FEBS Lett. 1995, 375, 117-120.
134. Facci, L.; Dal Toso, R.; Romanello, S.; Buriani, A.; Skaper, S. D.; Leon, A. Mast Cells Express a Peripheral Cannabinoid Receptor with Differential Sensitivity to Anandamide and Palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A 1995, 92, 3376-3380.
135. 2 Cannabinoid, as Potential Ligands for the Cannabinoid Receptors. Biochim. Biophys. Acta 1999, 1440, 266-274.
136. Sheskin, T.; Hanus, L.; Slager, J.; Vogel, Z.; Mechoulam, R. Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Cannabinoid Receptor. J. Med. Chem. 1997, 40, 659-667.
137. Lambert, D. M.; Vandevoorde, S.; Jonsson, K.-O.; Fowler, C. J. The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents? Curr. Med. Chem. 2002, 9, 663-674.
138. Walker, J. M.; Krey, J. F.; Chu, C. J.; Huang, S. M. Endocannabinoids and Related Fatty Acid Derivatives in Pain Modulation. Chem. Phys. Lipids 2002, 121, 159-172.
139. Mazzari, S.; Canella, R.; Petrelli, L.; Marcolongo, G.; Leon, A. N-(2-Hydroxyethyl)hexadecanamide Is Orally Active in Reducing Edema Formation and Inflammatory Hyperalgesia by Down-Modulating Mast Cell Activation. Eur. J. Pharmacol. 1996, 300, 227-236.
140. 2-Like Receptors. Pain 2002, 97, 11-21.
141. Costa, B.; Conti, S.; Giagnoni, G.; Colleoni, M. Therapeutic Effect of the Endogenous Fatty Acid Amide, Palmitoylethanolamide, in Rat Acute Inflammation: Inhibition of Nitric Oxide and Cyclo-Oxygenase Systems. Br. J. Pharmacol. 2002, 137, 413-420.
142. Conti, S.; Costa, B.; Colleoni, M.; Parolaro, D.; Giagnoni, G. Antiinflammatory Action of Endocannabinoid Palmitoylethanolamide and the Synthetic Cannabinoid Nabilone in a Model of Acute Inflammation in the Rat. Br. J. Pharmacol. 2002, 135, 181-187.
143. Lambert, D. M.; Vandevoorde, S.; Diependaele, G.; Govaerts, S. J.; Robert, A. R. Anticonvulsant Activity of N-Palmitoylethanolamide, a Putative Endocannabinoid, in Mice. Epilepsia 2001, 42, 321-327.
144. Di Marzo, V.; Melck, D.; Orlando, P.; Bisogno, T.; Zagoory, O.; Bifulco, M.; Vogel, Z.; De Petrocellis, L. Palmitoylethanolamide Inhibits the Expression of Fatty Acid Amide Hydrolase and Enhances the Anti-Proliferative Effect of Anandamide in Human Breast Cancer Cells. Biochem. J. 2001, 358, 249-255.
145. De Petrocellis, L.; Bisogno, T.; Ligresti, A.; Bifulco, M.; Melck, D.; Di Marzo, V. Effect on Cancer Cell Proliferation of Palmitoylethanolamide, a Fatty Acid Amide Interacting with Both the Cannabinoid and Vanilloid Signalling Systems. Fundam. Clin. Pharmacol. 2002, 16, 297-302.
146. Lo Verme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide. Mol. Pharmacol. 2005, 67, 15-19.
147. Maccarrone, M.; Pauselli, R.; Rienzo, M. D.; Finazzi-Agrò, A. Binding, Degradation and Apoptotic Activity of Stearoyl-ethanolamide in Rat C6 Glioma Cells. Biochem. J. 2002, 366, 137-144.
148. Gulaya, N. M.; Kuzmenko, A. I.; Margitich, V. M.; Govseeva, N. M.; Melnichuk, S. D.; Goridko, T. M.; Zhukov, A. D. Long-Chain N-Acylethanolamines Inhibit Lipid Peroxidation in Rat Liver Mitochondria under Acute Hypoxic Hypoxia. Chem. Phys. Lipids 1998, 97, 49-54.
149. Maccarrone, M.; Cartoni, A.; Parolaro, D.; Margonelli, A.; Massi, P.; Bari, M.; Battista, N.; Finazzi-Agrò, A. Cannabimimetic Activity, Binding, and Degradation of Stearoylethanolamide within the Mouse Central Nervous System. Mol. Cell. Neurosci. 2002, 21, 126-140.
150. Terrazzino, S.; Berto, F.; Carbonare, M. D.; Fabris, M.; Guiotto, A.; Bernardini, D.; Leon, A. Stearoylethanolamide Exerts Anorexic Effects in Mice via Downregulation of Liver Stearoyl-Coenzyme A Desaturase-1 mRNA Expression. FASEB J. 2004, 18, 1580-1582.
151. Rodriguez De Fonseca, F.; Navarro, M.; Gomez, R.; Escuredo, L.; Nava, F.; Fu, J.; Murillo-Rodriguez, E.; Giuffrida, A.; LoVerme, J.; Gaetani, S.; Kathuria, S.; Gall, C.; Piomelli, D. An Anorexic Lipid Mediator Regulated by Feeding. Nature 2001, 414, 209-212.
152. Oveisi, F.; Gaetani, S.; Eng, K. T.-P.; Piomelli, D. Oleoylethanolamide Inhibits Food Intake in Free-Feeding Rats after Oral Administration. Pharmacol. Res. 2004, 49, 461-466.
153. Nielsen, M. J.; Petersen, G.; Astrup, A.; Hansen, H. S. Food Intake Is Inhibited by Oral Oleoylethanolamide. J. Lipid Res. 2004, 45, 1027-1029.
154. Fu, J.; Gaetani, S.; Oveisi, F.; Lo Verme, J.; Serrano, A.; de Fonseca, F. R.; Rosengarth, A.; Luecke, H.; Di Giacomo, B.; Tarzia, G.; Piomelli, D. Oleylethanolamide Regulates Feeding and Body Weight through Activation of the Nuclear Receptor PPAR-α. Nature 2003, 425, 90-93.
155. Guzmán, M.; Lo Verme, J.; Fu, J.; Oveisi, F.; Blázquez, C.; Piomelli, D. Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α (PPAR α). J. Biol. Chem. 2004, 279, 27849-27854.
156. Burstein, S. H.; Huang, S. M.; Petros, T. J.; Rossetti, R. G.; Walker, J. M.; Zurier, R. B. Regulation of Anandamide Tissue Levels by N-Arachidonylglycine. Biochem. Pharmacol. 2002, 64, 1147-1150.
157. Gerard, C. M.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular Cloning of a Human Cannabinoid Receptor Which Is Also Expressed in Testis. Biochem. J. 1991, 279, 129-134.
158. Herkenham, M.; Lynn, A. B.; Little, M. D.; Johnson, M. R.; Melvin, L. S.; de Costa, B. R.; Rice, K. C. Cannabinoid Receptor Localization in Brain. Proc.
159. 2+ Channel Current. Am. J. Physiol: Heart Circ. Physiol. 1999, 276, H2085-H2093.
160. 1 Receptors in Mouse Brain and N18TG2 Neuroblastoma Cells. Biochem. Pharmacol. 1997, 53, 207-214.
161. 1 Cannabinoid Receptor Expression in Brain Regions Associated with Zebra Finch Song Control. Brain Res. 2000, 857, 151-157.
162. 1 Cannabinoid Receptor: Pharmacology and in Vivo and in Vitro Effects of Activation. J. Pharmacol. Exp. Ther. 2001, 297, 189-197.
163. Soderstrom, K.; Leid, M.; Moore, F. L.; Murray, T. F. Behavioral, Pharmacological, and Molecular Characterization of an Amphibian Cannabinoid Receptor. J. Neurochem. 2000, 75, 413-423.
164. Yamaguchi, F.; Macrae, A. D.; Brenner, S. Molecular Cloning of Two Cannabinoid Type 1-Like Receptor Genes from the Puffer Fish Fugu Rubripes. Genomics 1996, 35, 603-605.
165. Lutz, B. Molecular Biology of Cannabinoid Receptors. Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66, 123-142.
166. 1-Selective Cannabinoid Receptor Antagonist SR141716. Arch. Gen. Psychiatry 2001, 58, 322-328.
167. 2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains. J. Neurosci. 2003, 23, 11136-11141.
168. 2 Peripheral Cannabinoid Receptor. Biochim. Biophys. Acta 1996, 1307, 132-136.
169. 2 Cannabinoid Receptor. J. Pharmacol. Exp. Ther. 2000, 292, 886-894.
170. 2 Cannabinoid Receptor. Biochim. Biophys. Acta 2002, 1576, 255-264.
171. Howlett, A. C. Pharmacology of Cannabinoid Receptors. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 607-634.
172. 2 Receptors. Mol. Pharmacol. 1995, 48, 443-450.
173. Mackie, K.; Hille, B. Cannabinoids Inhibit N-Type Calcium Channels in Neuroblastoma-Glioma Cells. Proc. Natl. Acad. Sci. U.S.A 1992, 89, 3825-3829.
174. Deadwyler, S. A.; Hampson, R. E.; Mu, J.; Whyte, A.; Childers, S. Cannabinoids Modulate Voltage Sensitive Potassium A-Current in Hippocampal Neurons via a cAMP-Dependent Process. J. Pharmacol. Exp. Ther. 1995, 273, 734-743.
175. 1. Biochem. J. 1995, 312, 637-641.
176. 1 Induces Krox-24 Expression in Human Astrocytoma Cells. J. Biol. Chem. 1995, 270, 13973-13980.
177. Bouaboula, M.; Perrachon, S.; Milligan, L.; Canat, X.; Rinaldi, C. M.; Portier, M.; Barth, F.; Calandra, B.; Pecceu, F.; Lupker, J.; Maffrand, J. P.; Le Fur, G.; Casellas, P. A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-Activated Protein Kinase Activation Stimulated by Insulin or Insulin-Like Growth Factor 1. Evidence for a New Model of Receptor/Ligand Interactions. J. Biol. Chem. 1997, 272, 22330-22339.
178. + Exchanger NHE-1 Isoform via Gi-Mediated Mitogen Activated Protein Kinase Signaling Transduction Pathways. FEBS Lett. 1999, 449, 61-65.
179. 1 Receptor. Eur. J. Pharmacol. 1999, 374, 445-455.
180. Bonhaus, D. W.; Chang, L. K.; Kwan, J.; Martin, G. R. Dual Activation and Inhibition of Adenylyl Cyclase by Cannabinoid Receptor Agonists: Evidence for Agonist-Specific Trafficking of Intracellular Responses. J. Pharmacol. Exp. Ther. 1998, 287, 884-888.
181. 1 Receptor in Constitutive Activation of Gs. J. Neurochem. 1999, 72, 2032-2038.
182. 1 Receptor Knockout Mice. Proc. Natl. Acad. Sci. U.S.A 1999, 96, 5780-5785.
183. 1 Receptor Knockout Mice. Science 1999, 283, 401-404.
184. Marsicano, G.; Wotjak, C. T.; Azad, S. C.; Bisogno, T.; Rammes, G.; Cascio, M. G.; Hermann, H.; Tang, J.; Hofmann, C.; Zieglgänsberger, W.; Di Marzo, V.; Lutz, B. The Endogenous Cannabinoid System Controls Extinction of Aversive Memories. Nature 2002, 418, 530-534.
185. 1 Cannabinoid Receptors and On-Demand Defense against Excitotoxicity. Science 2003, 302, 84-88.
186. Paria, B. C.; Song, H.; Wang, X.; Schmid, P. C.; Krebsbach, R. J.; Schmid, H. H. O.; Bonner, T. L; Zimmer, A.; Dey, S. K. Dysregulated Cannabinoid Signaling Disrupts Uterine Receptivity for Embryo Implantation. J. Biol. Chem. 2001, 276, 20523-20528.
187. Wang, H.; Guo, Y.; Wang, D.; Kingsley, P. J.; Marnett, L. J.; Das, S. K.; DuBois, R. N.; Dey, S. K. Aberrant Cannabinoid Signaling Impairs Oviductal Transport of Embryos. Nat. Med. 2004, 10, 1074-1080.
188. 1 Receptor Knock-Out Mice. Eur. J. Pharmacol. 1999, 379, R1-R2.
189. 1 Receptor Knockout Mice in the Morris Water Maze. J. Pharmacol. Exp. Ther. 2002, 301, 915-924.
190. Di Marzo, V.; Goparaju, S. K.; Wang, L.; Liu, J.; Bátkai, S.; Járai, Z.; Fezza, F.; Miura, G. I.; Palmiter, R. D.; Sugiura, T.; Kunos, G. Leptin-Regulated Endocannabinoids Are Involved in Maintaining Food Intake. Nature 2001, 410, 822-825.
191. 1 Receptor Deleted Mice. Neurosci. Lett. 2003, 343, 216-218.
192. 1 Cannabinoid Receptor Knockout in Mice Leads to Leanness, Resistance to Diet-Induced Obesity and Enhanced Leptin Sensitivity. Int. J. Obes. 2004, 28, 640-648.
193. 1 Receptor Knockout Mice. Eur. J. Pharmacol. 1999, 383, R1-R2.
194. 1 Cannabinoid Receptors Modifies Nicotine Behavioural Responses, but Not Nicotine Abstinence. Neuropharmacology 2002, 43, 857-867.
195. 1 Cannabinoid Gene Disruption on Anxiety-Like and Social Behaviour in Mice. Eur. J. Neurosci. 2004, 19, 1906-1912.
196. 1 Receptors. Neuropharmacology 2004, 46, 966-973.
197. 1 Cannabinoid Receptor Knock-Out Mice. J. Neurosci. 2002, 22, 9771-9775.
198. 1 Receptor-Deficient Mice. Br. J. Pharmacol. 2001, 132, 1169-1173.
199. 1 Receptors Increases Noradrenaline Release in Vas Deferens without Affecting Atrial Noradrenaline Release or Cortical Acetylcholine Release. Br. J. Pharmacol. 2003, 140, 323-328.
200. 1 Receptor Mediates Retrograde Signals for Depolarization-Induced Suppression of Inhibition in Cerebellar Purkinje Cells. J. Neurosci. 2002, 22, 1690-1697.
201. 1 Receptor-Independent Action. Eur. J. Neurosci. 2003, 18, 1973-1978.
202. 1 Receptor Inverse Agonist AM251 in Mice. Behav. Pharmacol. 2003, 14, 573-582.
203. Pertwee, R. G. Pharmacology of Cannabinoid Receptor Ligands. Curr. Med. Chem. 1999, 6, 635-664.
204. Reggio, P. H. Pharmacophores for Ligand Recognition and Activation/Inactivation of the Cannabinoid Receptors. Curr. Pharm. Des. 2003, 9, 1607-1633.
205. Govaerts, S. J.; Hermans, E.; Lambert, D. M. Comparison of Cannabinoid Ligands Affinities and Efficacies in Murine Tissues and in Transfected Cells Expressing Human Recombinant Cannabinoid Receptors. Eur. J. Pharm. Sci. 2004, 23, 233-243.
206. Mauler, F.; Mittendorf, J.; Horvath, E.; de Vry, J. Characterization of the Diarylether Sulfonylester (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4, 4,4-trifluoro-1-sulfonate (BAY 38-7271) as a Potent Cannabinoid Receptor Agonist with Neuroprotective Properties. J. Pharmacol. Exp. Ther. 2002, 302, 359-368.
207. 1 Cannabinoid Receptor Agonist. Br. J. Pharmacol. 2004, 142, 495-500.
208. 1). J. Pharmacol. Exp. Ther. 1999, 289, 1427-1433.
209. 1 Vanilloid Receptor "Hybrid" Ligands. Biochem. Biophys. Res. Commun. 2001, 281, 444-451.
210. Zajicek, J.; Fox, P.; Sanders, H.; Wright, D.; Vickery, J.; Nunn, A.; Thompson, A. Cannabinoids for Treatment of Spasticity and Other Symptoms Related to Multiple Sclerosis (CAMS Study): Multicentre Randomised Placebo-Controlled Trial. Lancet 2003, 362, 1517-1526.
211. Smith, P. F. Medicinal Cannabis Extracts for the Treatment of Multiple Sclerosis. Curr. Opin. Invest. Drugs 2004, 5, 727-730.
212. Wiley, J. L.; LaVecchia, K. L.; Karp, N. E.; Kulasegram, S.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. A Comparison of the Discriminative Stimulus Effects of Delta(9)-Tetrahydrocannabinol and O-1812, a Potent and Metabolically Stable Anandamide Analog, in Rats. Exp. Clin. Psychopharmacol. 2004, 12, 173-179.
213. 2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects. J. Pharmacol. Exp. Ther. 2004, 310, 620-632.
214. 1 Receptors Inhibits Mechanically Evoked Responses of Spinal Neurons in Noninflamed Rats and Rats with Hindpaw Inflammation. Eur. J. Neurosci. 2003, 18, 2239-2243.
215. Johanek, L. M.; Simone, D. A. Activation of Peripheral Cannabinoid Receptors Attenuates Cutaneous Hyperalgesia Produced by a Heat Injury. Pain 2004, 109, 432-442.
216. Järvinen, T.; Pate, D. W.; Laine, K. Cannabinoids in the Treatment of Glaucoma. Pharmacol. Ther. 2002, 95, 203-220.
217. Fride, E.; Feigin, C.; Ponde, D. E.; Breuer, A.; Hanus, L.; Arshavsky, N.; Mechoulam, R. (+)-Cannabidiol Analogues Which Bind Cannabinoid Receptors but Exert Peripheral Activity Only. Eur. J. Pharmacol. 2004, 506, 179-188.
218. 2 Cannabinoid Receptor-Mediated Peripheral Antinociception. Pain 2001, 93, 239-245.
219. 2 Cannabinoid Receptors Are Implicated in Inflammatory Pain. Pain 2002, 96, 253-260.
220. 2 Cannabinoid Receptors. Anesthesiology 2003, 99, 955-960.
221. 2 Cannabinoid Receptors by AM1241 Inhibits Experimental Neuropathic Pain: Pain Inhibition by Receptors Not Present in the CNS. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10529-10533.
222. 2 Receptors Suppresses Spinal Fos Protein Expression and Pain Behavior in a Rat Model of Inflammation. Neuroscience 2003, 119, 747-757.
223. 2 Receptors Suppresses Hyperalgesia Evoked by Intradermal Capsaicin. J. Pharmacol. Exp. Ther. 2004, 308, 446-453.
224. 2 Cannabinoid Receptor Activation Produces Antinociception by Stimulating Peripheral Release of Endogenous Opioids. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3093-3098.
225. 2 Cannabinoid Receptor. Cancer Res. 2001, 61, 5784-5789.
226. Blázquez, C.; Casanova, M. L.; Planas, A.; del Pulgar, T. G.; Villanueva, C.; Fernández-Aceñero, M. J.; Aragonés, J.; Huffman, J. W.; Jorcano, J. L.; Guzmán, M. Inhibition of Tumor Angiogenesis by Cannabinoids. FASEB J. 2003, 17, 529-531.
227. 1 Receptor Antagonists. Curr. Opin. Drug Discovery Dev. 2004, 7, 498-506.
228. Muccioli, G. G.; Lambert, D. M. Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors. Curr. Med. Chem. 2005, 12, 1361-1384.
229. 1, Receptor Antagonist, SR 141716, on Food Intake and Body Weight Gain of Obese (fa/fa) Compared to Lean Zucker Rats. Psychopharmacology 2003, 167, 103-111.
230. 1) Receptor Antagonist, Blocks the Motivational and Dopamine-Releasing Effects of Nicotine in Rats. Behav. Pharmacol. 2002, 13, 451-463.
231. Van Gaal, L. F.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rössner, S. Effects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-Year Experience from the RIO-Europe Study. Lancet 2005, 365, 1389-1397.
232. Cleland, J. G. F.; Ghosh, J.; Freemantle, N.; Kaye, G. C.; Nasir, M.; Clark, A. L.; Coletta, A. P. Clinical Trials Update and Cumulative Meta-Analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and Cardiac Resynchronisation Therapy in Heart Failure. Eur. J. Heart Failure 2005, 6, 501-508.
233. 1 Receptor to Stimulation of cAMP Accumulation. J. Pharmacol. Exp. Ther. 1998, 284, 291-297.
234. 1 Cannabinoid Receptor Antagonists. J. Med. Chem. 2004, 47, 627-643.
235. 1 Receptors. Eur. J. Pharmacol. 1996, 307, 331-338.
236. 1 Selective Cannabinoid Antagonist AM281: A Potential Human SPECT Ligand. AAPS PharmSci 1999, 1, U13-U24.
237. 9-Tetrahydrocannabinol Therapy and Whole-Body Scanning for Assessment of Radiation Dose in Tourette Patients. Biol. Psychiatry 2004, 55, 904-915.
238. 1 Receptor. Eur. J. Pharmacol. 1997, 334, R1-R2.
239. 2 Cannabinoid Receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 1999, 126, 665-672.
240. 1 Receptor Antagonist. Eur. J. Pharmacol. 2004, 487, 213-221.
241. Kanyonyo, M.; Govaerts, S. J.; Hermans, E.; Poupaert, J. H.; Lambert, D. M. 3-Alkyl-(5,5′-diphenyl)imidazolidinediones as New Cannabinoid Receptor Ligands. Bioorg. Med. Chem. Lett. 1999, 9, 2233-2236.
242. 1 Cannabinoid Receptor Ligands and Potential Antagonists: Synthesis, Lipophilicity, Affinity, and Molecular Modeling. J. Med. Chem. 2002,45, 1748-1756.
243. 2 Receptors. Eur. J. Pharmacol. 2004, 495, 43-53.
244. 1 Cannabinoid Receptor Ligands: Synthesis and Pharmacological Evaluation. J. Med. Chem. 2005 48, 2509-2517.
245. Martin, B. R.; Jefferson, R.; Winckler, R.; Wiley, J. L.; Huffman, J. W.; Crocker, P. J.; Saha, B.; Razdan, R. K. Manipulation of the Tetrahydrocannabinol Side Chain Delineates Agonists, Partial Agonists, and Antagonists. J. Pharmacol. Exp. Ther. 1999, 290, 1065-1079.
246. 2 Cannabinoid Receptors. J. Med. Chem. 2000, 43, 2300-2309.
247. Murphy, J. W.; Kendall, D. A. Integrity of Extracellular Loop 1 of the Human Cannabinoid Receptor 1 Is Critical for High-Affinity Binding of the Ligand CP 55,940 but Not SR 141716A. Biochem. Pharmacol. 2003, 65, 1623-1631.
248. 1 Receptor Constitutes an Agonist/Inverse Agonist Binding Region. J. Med. Chem. 2003, 46, 5139-5152.
249. Barnett-Norris, J.; Guarnieri, F.; Hurst, D. P.; Reggio, P. H. Exploration of Biologically Relevant Conformations of Anandamide, 2-Arachidonylglycerol, and Their Analogues Using Conformational Memories. J. Med. Chem. 1998, 41, 4861-4872.
250. 1 Receptor. J. Med. Chem. 2002, 45, 3649-3659.
251. 1 Receptor Activation. J. Biol. Chem. 2004, 279, 48024-48037.
252. 1 Receptor Selectively Disrupts G Protein Signaling and Prevents Receptor Internalization. Mol. Pharmacol. 1999, 56, 611-618.
253. 2 Cannabinoid Receptor. FEBS Lett. 2000, 466, 300-304.
254. 1 Receptor-G Protein Association. Subtype Selectivity Is Determined by Distinct Intracellular Domains. Eur. J. Biochem. 2001, 268, 499-505.
255. 1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism. J. Biol. Chem. 2001, 276, 12856-12863.
256. 1 Receptors. Br. J. Pharmacol. 2003, 140, 1451-1459.
257. Liao, C.; Zheng, J.; David, L. S.; Nicholson, R. A. Inhibition of Voltage-Sensitive Sodium Channels by the Cannabinoid 1 Receptor Antagonist AM 251 in Mammalian Brain. Pharmacol. Toxicol. 2004, 94, 73-78.
258. 3" Receptor. Eur. J. Pharmacol. 2003, 461, 27-34.
259. 2 Receptors. Am. J. Physiol.: Heart Circ. Physiol. 2004, 287, H595-H600.
260. 9-Tetrahydrocannabinol Are Neuroprotective Antioxidants. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 8268-8273.
261. 3A Receptors: Probable Involvement of an Allosteric Modulatory Site. Br. J. Pharmacol. 2002, 137, 589-596.
262. 2-Cannabinoid Receptor-Independent Lipolysis Induced by WIN 55,212-2 in Male Rat Adipocytes. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 368, 352-359.
263. 1 Knock-out and Wild-Type Mice. J. Pharmacol. Exp. Ther. 2004, 309, 86-91.
264. Jordt, S. E.; Bautista, D. M.; Chuang, H. H.; McKemy, D. D.; Zygmunt, P. M.; Högestätt, E. D.; Meng, I. D.; Julius, D. Mustard Oils and Cannabinoids Excite Sensory Nerve Fibres through the TRP Channel ANKTM1. Nature 2004, 427, 260-265.
265. Baker, C. L.; McDougall, J. J. The Cannabinomimetic Arachidonyl-2- chloroethylamide (ACEA) Acts on Capsaicin-Sensitive TRPV1 Receptors but Not Cannabinoid Receptors in Rat Joints. Br. J. Pharmacol. 2004, 142, 1361-1367.
266. Gardner, B.; Zhu, L. X.; Sharma, S.; Tashkin, D. P.; Dubinett, S. M. Methanandamide Increases COX-2 Expression and Tumor Growth in Murine Lung Cancer. FASEB J. 2003, 17, 2157-2159.
267. Ramer, R.; Weinzierl, U.; Schwind, B.; Brune, K.; Hinz, B. Ceramide Is Involved in R(+)-Methanandamide-Induced Cyclooxygenase-2 Expression in Human Neuroglioma Cells. Mol. Pharmacol. 2003, 64, 1189-1198.
268. Bueb, J. L.; Lambert, D. M.; Tschirhart, E. J. Receptor-Independent Effects of Natural Cannabinoids in Rat Peritoneal Mast Cells in Vitro. Biochim. Biophys. Acta 2001, 1538, 252-259.
269. +-ATPase. Neurochem. Int. 2004, 44, 529-538.
270. Duncan, M.; Kendall, D. A.; Ralevic, V. Characterization of Cannabinoid Modulation of Sensory Neurotransmission in the Rat Isolated Mesenteric Arterial Bed. J. Pharmacol. Exp. Ther. 2004, 311, 411-419.
271. Pertwee, R. G.; Gibson, T. M.; Stevenson, L. A.; Ross, R. A.; Banner, W. K.; Saha, B.; Razdan, R. K.; Martin, B. R. O-1057, a Potent Water-Soluble Cannabinoid Receptor Agonist with Antinociceptive Properties. Br. J. Pharmacol. 2000, 129, 1577-1584.
272. 1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization. J. Pharmacol. Exp. Ther. 2004, 310, 905-914.
273. Fowler, C. J.; Jacobsson, S. O. P. Cellular Transport of Anandamide, 2-Arachidonoylglycerol and Palmitoylethanolamide - Targets for Drug Development? Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66, 193-200.
274. Hájos, N.; Kathuria, S.; Dinh, T.; Piomelli, D.; Freund, T. F. Endocannabinoid Transport Tightly Controls 2-Arachidonoyl Glycerol Actions in the Hippocampus: Effects of Low Temperature and the Transport Inhibitor AM404. Eur. J. Neurosci. 2004, 19, 2991-2996.
275. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J. C.; Piomelli, D. Formation and Inactivation of Endogenous Cannabinoid Anandamide in Central Neurons. Nature 1994, 372, 686-691.
276. Hillard, C. J.; Edgemond, W. S.; Jarrahian, A.; Campbell, W. B. Accumulation of N-Arachidonoylethanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated Diffusion. J. Neurochem. 1997, 69, 631-638.
277. Deutsch, D. G.; Glaser, S. T.; Howell, J. M.; Kunz, J. S.; Puffenbarger, R. A.; Hillard, C. J.; Anbumrad, N. The Cellular Uptake of Anandamide Is Coupled to Its Breakdown by Fatty-Acid Amide Hydrolase. J. Biol. Chem. 2001, 276, 6967-6973.
278. Day, T. A.; Rakhshan, F.; Deutsch, D. G.; Barker, E. L. Role of Fatty Acid Amide Hydrolase in the Transport of the Endogenous Cannabinoid Anandamide. Mol. Pharmacol. 2001, 59, 1369-1375.
279. Glaser, S. T.; Abumrad, N. A.; Fatade, F.; Kaczocha, M.; Studholme, K. M.; Deutsch, D. G. Evidence against the Presence of an Anandamide Transporter. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4269-4274.
280. Ligresti, A.; Morera, E.; van der Stelt, M.; Monory, K.; Lutz, B.; Ortar, G.; Di Marzo, V. Further Evidence for the Existence of a Specific Process for the Membrane Transport of Anandamide. Biochem. J. 2004, 380, 265-272.
281. Fegley, D.; Kathuria, S.; Mercier, R.; Li, C.; Goutopoulos, A.; Makriyannis, A.; Piomelli, D. Anandamide Transport Is Independent of Fatty-Acid Amide Hydrolase Activity and Is Blocked by the Hydrolysis-Resistant Inhibitor AM1172. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 8756-8761.
282. 1 Receptor to Anandamide Uptake. Biochemistry 2004, 43, 8184-8190.
283. McFarland, M. J.; Porter, A. C.; Rakhshan, F. R.; Rawat, D. S.; Gibbs, R. A.; Barker, E. L. A Role for Caveolae/Lipid Rafts in the Uptake and Recycling of the Endogenous Cannabinoid Anandamide. J. Biol. Chem. 2004, 279, 41991-41997.
284. Hillard, C. J.; Jarrahian, A. Cellular Accumulation of Anandamide: Consensus and Controversy. Br. J. Pharmacol. 2003, 140, 802-808.
285. Bojesen, I. N.; Hansen, H. S. Binding of Anandamide to Bovine Serum Albumin. J. Lipid Res. 2003, 44, 1790-1794.
286. Fowler, C. J.; Tiger, G.; Ligresti, A.; López-Rodríguez, M. L.; Di Marzo, V. Selective Inhibition of Anandamide Cellular Uptake versus Enzymatic Hydrolysis - A Difficult Issue to Handle. Eur. J. Pharmacol. 2004, 492, 1-11.
287. Ramakrishnan, M.; Kenoth, R.; Kamlekar, R. K.; Chandra, M. S.; Radhakrishnan, T. P.; Swamy, M. J. N-Myristoylethanolamine - Cholesterol (1:1) Complex: First Evidence from Differential Scanning Calorimetry, Fast-Atom-Bombardment Mass Spectrometry and Computational Modelling. FEBS Lett. 2002, 531, 343-347.
288. Sarker, K. P.; Maruyama, I. Anandamide Induces Cell Death Independently of Cannabinoid Receptors or Vanilloid Receptor 1: Possible Involvement of Lipid Rafts. Cell. Mol. Life Sci. 2003, 60, 1200-1208.
289. Biswas, K. K.; Sarker, K. P.; Abeyama, K.; Kawahara, K.; Iino, S.; Otsubo, Y.; Saigo, K.; Izumi, H.; Hashiguchi, T.; Yamakuchi, M.; Yamaji, K.; Endo, R.; Suzuki, K.; Imaizumi, H.; Maruyama, I. Membrane Cholesterol but Not Putative Receptors Mediates Anandamide-Induced Hepatocyte Apoptosis. Hepatology 2003, 38, 1167-1177.
290. Karlsson, M.; Påhlsson, C.; Fowler, C. J. Reversible, Temperature-Dependent, and AM404-Inhibitable Adsorption of Anandamide to Cell Culture Wells as a Confounding Factor in Release Experiments. Eur. J. Pharm. Sci. 2004, 22, 181-189.
291. Beltramo, M.; Stella, N.; Calignano, A.; Lin, S. Y.; Makriyannis, A.; Piomelli, D. Functional Role of High-Affinity Anandamide Transport, As Revealed by Selective Inhibition. Science 1997, 277, 1094-1097.
292. Zygmunt, P. M.; Chuang, H. H.; Movahed, P.; Julius, D.; Högestätt, E. D. The Anandamide Transport Inhibitor AM404 Activates Vanilloid Receptors. Eur. J. Pharmacol. 2000, 396, 39-42.
293. De Petrocellis, L.; Bisogno, T.; Davis, J. B.; Pertwee, R. G.; Di Marzo, V. Overlap between the Ligand Recognition Properties of the Anandamide Transporter and the VR1 Vanilloid Receptor: Inhibitors of Anandamide Uptake with Negligible Capsaicin-like Activity. FEBS Lett. 2000, 483, 52-56.
294. 2+, Questioning Its Selectivity as a Pharmacological Tool for Investigating the Anandamide Transporter. J. Pharmacol. Toxicol. Methods 2001, 45, 195-198.
295. Jonsson, K.-O.; Andersson, A.; Jacobsson, S. O. P.; Vandevoorde, S.; Lambert, D. M.; Fowler, C. J. AM404 and VDM 11 Non-Specifically Inhibit C6 Glioma Cell Proliferation at Concentrations Used To Block the Cellular Accumulation of the Endocannabinoid Anandamide. Arch. Toxicol. 2003, 77, 201-207.
296. 1 Receptors. Eur. J. Pharmacol. 2004, 496, 33-39.
297. Jarrahian, A.; Manna, S.; Edgemond, W. S.; Campbell, W. B.; Hillard, C. J. Structure-Activity Relationships among N-Arachidonylethanolamine (Anandamide) Head Group Analogues for the Anandamide Transporter. J. Neurochem. 2000, 74, 2597-2606.
298. Piomelli, D.; Beltramo, M.; Glasnapp, S.; Lin, S. Y.; Goutopoulos, A.; Xie, X. Q.; Makriyannis, A. Structural Determinants for Recognition and Translocation by the Anandamide Transporter. Proc. Natl. Acad. Sci. U.S.A 1999, 96, 5802-5807.
299. Di Marzo, V.; Ligresti, A.; Morera, E.; Nalli, M.; Ortar, G. The Anandamide Membrane Transporter. Structure-Activity Relationships of Anandamide and Oleoylethanolamine Analogs with Phenyl Rings in the Polar Head Group Region. Bioorg. Med. Chem. 2004, 12, 5161-5169.
300. López-Rodríguez, M. L.; Viso, A.; Ortega-Gutiérrez, S.; Fowler, C. J.; Tiger, G.; de Lago, E.; Fernández-Ruiz, J.; Ramos, J. A. Design, Synthesis, and Biological Evaluation of New Inhibitors of the Endocannabinoid Uptake: Comparison with Effects on Fatty Acid Amidohydrolase. J. Med. Chem. 2003, 46, 1512-1522.
301. Ortar, G.; Ligresti, A.; De Petrocellis, L.; Morera, E.; Di Marzo, V. Novel Selective and Metabolically Stable Inhibitors of Anandamide Cellular Uptake. Biochem. Pharmacol. 2003, 65, 1473-1481.
302. Fowler, C. J.; Holt, S.; Nilsson, J.; Jonsson, K.-O.; Tiger, G.; Jacobsson, S. O. P. The endocannabinoid signalling system: pharmacological and therapeutic aspects. Pharmacol. Biochem. Behav. 2005, 81, 248-262.
303. de Lago, E.; Ligresti, A.; Ortar, G.; Morera, E.; Cabranes, A.; Pryce, G.; Bifulco, M.; Baker, D.; Fernández-Ruiz, J.; Di Marzo, V. In Vivo Pharmacological Actions of Two Novel Inhibitors of Anandamide Cellular Uptake. Eur. J. Pharmacol. 2004, 484, 249-257.
304. Hopkins, S. C.; Wang, F. Inhibitors of anandamide uptake lacking arachidonoyl chain. 2004 Symposium on the Cannabinoids; International Cannabinoid Research Society: Burlington, VT, 2004; p 103.
305. Bachur, N. R.; Udenfriend, S. Microsomal Synthesis of Fatty Acid Amides. J. Biol. Chem. 1966, 241, 1308-1313.
306. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular Characterization of an Enzyme That Degrades Neuromodulatory Fatty-Acid Amides. Nature 1996, 384, 83-87.
307. Deutsch, D. G.; Ueda, N.; Yamamoto, S. The Fatty Acid Amide Hydrolase (FAAH). Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66, 201-210.
308. Ueda, N. Endocannabinoid Hydrolases. Prostaglandins Other Lipid Mediators 2002, 68-69, 521-534.
309. Cravatt, B. F.; Lichtman, A. H. Fatty Acid Amide Hydrolase: An Emerging Therapeutic Target in the Endocannabinoid System. Curr. Opin. Chem. Biol. 2003, 7, 469-475.
310. Fowler, C. J. Metabolism of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol, a Review, with Emphasis on the Pharmacology of Fatty Acid Amide Hydrolase, a Possible Target for the Treatment of Neurodegenerative Diseases and Pain. Curr. Med. Chem.: Cent. Nerv. Syst. Agents 2004, 4, 161-174.
311. McPartland, J. M. Phylogenomic and Chemotaxonomic Analysis of the Endocannabinoid System. Brain Res. Rev. 2004, 45, 18-29.
312. McKinney, M. K.; Cravatt, B. J. Structrue and Function of Fatty Acid Amide Hydrolase. Annu. Rev. Biochem. 2005, 74, 411-432.
313. Vandevoorde, S.; Lambert, D. M. Focus on the Three Key Enzymes Hydrolyzing Endocannabinoids as New Drug Targets. Curr. Pharm. Des., in press.
314. Giang, D. K.; Cravatt, B. F. Molecular Characterization of Human and Mouse Fatty Acid Amide Hydrolases. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2238-2242.
315. Goparaju, S. K.; Ueda, N.; Taniguchi, K.; Yamamoto, S. Enzymes of Porcine Brain Hydrolyzing 2-Arachidonoylglycerol, an Endogenous Ligand of Cannabinoid Receptors. Biochem. Pharmacol. 1999, 57, 417-423.
316. Ueda, N.; Yamamoto, S. Anandamide Amidohydrolase (Fatty Acid Amide Hydrolase). Prostaglandins Other Lipid Mediators 2000, 61, 19-28.
317. Ueda, N.; Puffenbarger, R. A.; Yamamoto, S.; Deutsch, D. G. The Fatty Acid Amide Hydrolase (FAAH). Chem. Phys. Lipids 2000, 108, 107-121.
318. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. Science 2002, 298, 1793-1796.
319. Desarnaud, F.; Cadas, H.; Piomelli, D. Anandamide Amidohy-drolase Activity in Rat Brain Microsomes. Identification and Partial Characterization. J. Biol. Chem. 1995, 270, 6030-6035.
320. Katayama, K.; Ueda, N.; Kurahashi, Y.; Suzuki, H.; Yamamoto, S.; Kato, I. Distribution of Anandamide Amidohydrolase in Rat Tissues with Special Reference to Small Intestine. Biochim. Biophys. 1997, 1347, 212-218.
321. Valenti, M.; Vigano, D.; Casico, M. G.; Rubino, T.; Steardo, L.; Parolaro, D.; Di Marzo, V. Differential Diurnal Variations of Anandamide and 2-Arachidonoyl-Glycerol Levels in Rat Brain. Cell. Mol. Life Sci. 2004, 61, 945-950.
322. Paria, B. C.; Deutsch, D. D.; Dey, S. K. The Uterus Is a Potential Site for Anandamide Synthesis and Hydrolysis: Differential Profiles of Anandamide Synthase and Hydrolase Activities in the Mouse Uterus during the Periimplantation Period. Mol. Reprod. Dev. 1996, 45, 183-192.
323. Paria, B. C.; Zhao, X.; Wang, J.; Das, S. K.; Dey, S. K. Fatty-Acid Amide Hydrolase Is Expressed in the Mouse Uterus and Embryo during the Periimplantation Period. Biol. Reprod. 1999, 60, 1151-1157.
324. Sipe, J. C.; Chiang, K.; Gerber, A. L.; Beutler, E.; Cravatt, B. F. A Missense Mutation in Human Fatty Acid Amide Hydrolase Associated with Problem Drug Use. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 8394-8399.
325. Chiang, K. P.; Gerber, A. L.; Sipe, J. C.; Cravatt, B. F. Reduced Cellular Expression and Activity of the P129T Mutant of Human Fatty Acid Amide Hydrolase: Evidence for a Link between Defects in the Endocannabinoid System and Problem Drug Use. Hum. Mol. Genet. 2004, 13, 2113-2119.
326. Maccarrone, M.; Valensise, H.; Bari, M.; Lazzarin, N.; Romanini, C.; Finazzi-Agrò, A. Progesterone Up-Regulates Anandamide Hydrolase in Human Lymphocytes: Role of Cytokines and Implications for Fertility. J. Immunol. 2001, 166, 7183-7189.
327. Maccarrone, M.; Di Rienzo, M.; Finazzi-Agrò, A.; Rossi, A. Leptin Activates the Anandamide Hydrolase Promoter in Human T Lymphocytes through STAT3. J. Biol. Chem. 2003, 278, 13318-13324.
328. Lazzarin, N.; Valensise, H.; Bari, M.; Ubaldi, F.; Battista, N.; Finazzi-Agrò, A.; Maccarrone, M. Fluctuations of Fatty Acid Amide Hydrolase and Anandamide Levels during the Human Ovulatory Cycle. Gynecol. Endocrinol. 2004, 18, 212-218.
329. Maccarrone, M.; Valensise, H.; Bari, M.; Lazzarin, M.; Romanini, C.; Finazzi-Agrò, A. Relation between Decreased Anandamide Hydrolase Concentrations in Human Lymphocytes and Miscarriage. Lancet 2000, 355, 1326-1329.
330. Goparaju, S. K.; Ueda, N.; Yamaguchi, H.; Yamamoto, S. Anandamide Amidohydrolase Reacting with 2-Arachidonoyl-glycerol, Another Cannabinoid Receptor Ligand. FEBS Lett. 1998, 422, 69-73.
331. Ikeda, Y.; Okamura, K.; Fujii, S. Purification and Characterization of Rat Liver Microsomal Monoacylglycerol Lipase in Comparison to the Other Esterases. Biochim. Biophys. Acta 1977, 488, 128-139.
332. Cravatt, B. F.; Demarest, K.; Patricelli, M. P.; Bracey, M. H.; Giang, D. K.; Martin, B. R.; Lichtman, A. H. Supersensitivity to Anandamide and Enhanced Endogenous Cannabinoid Signaling in Mice Lacking Fatty Acid Amide Hydrolase. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9371-9376.
333. Clement, A. B.; Hawkins, E. G.; Lichtman, A. H.; Cravatt, B. F. Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide Hydrolase. J. Neurosci. 2003, 23, 3916-3923.
334. Cravatt, B. F.; Saghatelian, A.; Hawkins, E. G.; Clement, A. B.; Bracey, M. H.; Lichtman, A. H. Functional Disassociation of the Central and Peripheral Fatty Acid Amide Signaling Systems. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 10821-10826.
335. Piomelli, D.; Giuffrida, A.; Calignano, A.; de Fonseca, F. R. The Endocannabinoid System as a Target for Therapeutic Drugs. Trends Pharmacol. Sci. 2000, 21, 218-224.
336. Fowler, C. J. Plant-Derived, Synthetic and Endogenous Cannabinoids as Neuroprotective Agents: Non-Psychoactive Cannabinoids, "Entourage" Compounds and Inhibitors of N-Acyl Ethanolamine Breakdown as Therapeutic Strategies To Avoid Pyschotropic Effects. Brain Res. Rev. 2003, 41, 26-43.
337. Cravatt, B. F.; Lichtman, A. H. Fatty Acid Amide Hydrolase: An Emerging Therapeutic Target in the Endocannabinoid System. Curr. Opin. Chem. Biol. 2003, 7, 469-475.
338. Hillard, C.; Wilkison, D.; Edgemond, W.; Campbell, W. Characterization of the Kinetics and Distribution of N-Arachidonylethanolamine (anandamide) Hydrolysis by Rat Brain. Biochim. Biophys. Acta 1995, 1257, 249-256.
339. Deutsch, D. G.; Omeir, R.; Arreaza, G.; Salehani, D.; Prestwich, G. D.; Huang, Z.; Hewlett, A. Methyl Arachidonyl Fluorophosphonate: A Potent Irreversible Inhibitor of Anandamide Amidase. Biochem. Pharmacol. 1997, 53, 255-260.
340. De Petrocellis, L.; Melck, D.; Ueda, N.; Maurelli, S.; Kurahashi, Y.; Yamamoto, S.; Marino, G.; Di Marzo, V. Novel Inhibitors of Brain, Neuronal, and Basophilic Anandamide Amidohydrolase. Biochem. Biophys. Res. Commun. 1997, 231, 82-88.
341. Edgemond, W. S.; Greenberg, M. J.; McGinley, P. J.; Muthian, S.; Campbell, W. B.; Hillard, C. J. Synthesis and Characterization of Diazomethylarachidonyl Ketone: An Irreversible Inhibitor of Af- Arachidonylethanolamine Amidohydrolase. J. Pharmacol. Exp. Ther. 1998, 286, 184-190.
342. Deutsch, D. G.; Lin, S.; Hill, W. A.; Morse, K. L.; Salehani, D.; Arreaza, G.; Omeir, R. L.; Makriyannis, A. Fatty Acid Sulfonyl Fluorides Inhibit Anandamide Metabolism and Bind to the Cannabinoid Receptor. Biochem. Biophys. Res. Commun. 1997, 231, 217-221.
343. Martin, B. R.; Beletskaya, I.; Patrick, G.; Jefferson, R.; Winckler, R.; Deutsch, D. G.; Di Marzo, V.; Dasse, O.; Mahadevan, A.; Razdan, R. K. Cannabinoid Properties of Methylfluorophosphonate Analogs. J. Pharmacol. Exp. Ther. 2000, 294, 1209-1218.
344. 1 Receptor and Fatty Acid Amide Hydrolase Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 3301-3303.
345. Beltramo, M.; di Tomaso, E.; Piomelli, D. Inhibition of Anandamide Hydrolysis in Rat Brain Tissue by (E)-6-(Bromomethylene) Tetrahydro-3-(1- naphthalenyl)-2H-pyran-2-one. FEBS Lett. 1997, 403, 263-267.
346. Patricelli, M. P.; Patterson, J. E.; Boger, D. L.; Cravatt, B. F. An Endogenous Sleep-Inducing Compound Is a Novel Competitive Inhibitor of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 1998, 8, 613-618.
347. Fegley, D.; Gaetani, S.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Piomelli, D. Characterization of the Fatty-Acid Amide Hydrolase Inhibitor URB597: Effects on Anandamide and Oleoylethanolamide Deactivation. J. Pharmacol. Exp. Ther. 2005, 313, 352-358.
348. Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, Synthesis, and Structure-Activity Relationships of Alkylcarbamic Acid Aryl Esters, a New Class of Fatty Acid Amide Hydrolase Inhibitors. J. Med. Chem. 2003, 46, 2352-2360.
349. Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic Acid 3′- or 4′-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships, and Molecular Modeling Studies. J. Med. Chem. 2004, 47, 4998-5008.
350. Basso, E.; Duranti, A.; Mor, M.; Piomelli, D.; Tontini, A.; Tarzia, G.; Traldi, P. Tandem Mass Spectrometric data-FAAH Inhibitory Activity Relationships of Some Carabamic Acid O-Aryl Esters. J. Mass Spectrom. 2004, 39, 1450-1455.
351. Koutek, B.; Prestwich, G. D.; Howlett, A. C.; Chin, S. A.; Salehani, D.; Akhavan, N.; Deutsch, D. G. Inhibitors of Arachidonoyl Ethanolamide Hydrolysis. J. Biol. Chem. 1994, 269, 22937-22940.
352. Patterson, J. E.; Ollmann, I. R.; Cravatt, B. F.; Boger, D. L.; Wong, C. H.; Lerner, R. A. Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipid cis-9-Octadecenamide. J. Am. Chem. Soc. 1996, 118, 5938-5945.
353. Boger, D. L.; Sato, H.; Lerner, A. E.; Austin, B. J.; Patterson, J. E.; Patricelli, M. P.; Cravatt, B. F. Trifluoromethyl Ketone Inhibitors of Fatty Acid Amide Hydrolase: A Probe of Structural and Conformational Features Contributing to Inhibition. Bioorg. Med. Chem. Lett. 1999, 9, 265-270.
354. Jonsson, K.-O.; Vandevoorde, S.; Lambert, D. M.; Tiger, G.; Fowler, C. J. Effects of Homologues and Analogues of Palmitoylethanolamide upon the Inactivation of the Endocannabinoid Anandamide. Br. J. Pharmacol. 2001, 133, 1263-1275.
355. Vandevoorde, S.; Jonsson, K.-O.; Fowler, C. J.; Lambert, D. M. Modifications of the Ethanolamine Head in N-Palmitoylethanolamine: Synthesis and Evaluation of New Agents Interfering with the Metabolism of Anandamide. J. Med. Chem. 2003, 46, 1440-1448.
356. Bisogno, T.; Melck, D.; De Petrocellis, L.; Bobrov, M. Y.; Gretskaya, N. M.; Bezuglov, V. V.; Sitachitta, N.; Gerwick, W. H.; Di, M. V. Arachidonoylserotonin and Other Novel Inhibitors of Fatty Acid Amide Hydrolase. Biochem. Biophys. Res. Commun. 1998, 248, 515-522.
357. 1 Cannabinoid-Receptor Ligands and Inhibitors of Anandamide Inactivation with Cannabimimetic Activity in Vitro and in Vivo. Biochem. J. 2000, 351, 817-824.
358. Boger, D. L.; Sato, H.; Lerner, A. E.; Hedrick, M. P.; Fecik, R. A.; Miyauchi, H.; Wilkie, G. D.; Austin, B. J.; Patricelli, M. P.; Cravatt, B. F. Exceptionally Potent Inhibitors of Fatty Acid Amide Hydrolase: The Enzyme Responsible for Degradation of Endogenous Oleamide and Anandamide. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5044-5049.
359. Boger, D. L.; Miyauchi, H.; Hedrick, M. P. Alpha-Keto Heterocycle Inhibitors of Fatty Acid Amide Hydrolase: Carbonyl Group Modification and Alpha-Substitution. Bioorg. Med. Chem. Lett. 2001, 11, 1517-1520.
360. Lichtman, A. H.; Leung, D.; Shelton, C. C.; Saghatelian, A.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity. J. Pharmacol. Exp. Ther. 2004, 311, 441-448.
361. Leung, D.; Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Discovery of an Exceptionally Potent and Selective Class of Fatty Acid Amide Hydrolase Inhibitors Enlisting Proteome-Wide Selectivity Screening: Concurrent Optimization of Enzyme Inhibitor Potency and Selectivity. Bioorg. Med. Chem. Lett. 2005, 15, 1423-1428.
362. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimarães, C. R. W.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a Potent, Selective, and Efficacious Class of Reversible a-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Effective as Analgesics. J. Med. Chem. 2005, 48, 1849-1856.
363. Watanabe, K.; Kayano, Y.; Matsunaga, T.; Yamamoto, I.; Yoshimura, H. Inhibition of Anandamide Amidase Activity in Mouse Brain Microsomes by Cannabinoids. Biol. Pharm. Bull. 1996, 19, 1109-1111.
364. 1 Receptors and on the Cellular Uptake and Enzymatic Hydrolysis of Anandamide. Br. J. Pharmacol. 2001, 134, 845-852.
365. Rhee, M. H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; Breuer, A.; Mechoulam, R. Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylylcyclase. J. Med. Chem. 1997, 40, 3228-3233.
366. Watanabe, K.; Ogi, H.; Nakamura, S.; Kayano, Y.; Matsunaga, T.; Yoshimura, H.; Yamamoto, I. Distribution and Characterization of Anandamide Amidohydrolase in Mouse Brain and Liver. Life Sci. 1998, 62, 1223-1229.
367. Fowler, C. J.; Tiger, G.; Stenström, A. Ibuprofen Inhibits Rat Brain Deamidation of Anandamide at Pharmacologically Relevant Concentrations. Mode of Inhibition and Structure-Activity Relationship. J. Pharmacol. Exp. Ther. 1997, 283, 729-734.
368. Fowler, C. J.; Janson, U.; Johnson, R. M.; Wahlström, G.; Stenström, A.; Norström, A.; Tiger, G. Inhibition of Anandamide Hydrolysis by the Enantiomers of Ibuprofen, Ketorolac, and Flurbiprofen. Arch. Biochem. Biophys. 1999, 362, 191-196.
369. Fowler, C. J.; Börjesson, M.; Tiger, G. Differences in the Pharmacological Properties of Rat and Chicken Brain Fatty Acid Amidohydrolase. Br. J. Pharmacol. 2000, 131, 498-504.
370. Patel, S.; Wohlfeil, E. R.; Rademacher, D. J.; Carrier, E. J.; Perry, L. J.; Kundu, A.; Falck, J. R.; Nithipatikom, K.; Campbell, W. B.; Hillard, C. J. The General Anesthetic Propofol Increases Brain N-Arachidonylethanolamine (Anandamide) Content and Inhibits Fatty Acid Amide Hydrolase. Br. J. Pharmacol. 2003, 139, 1005-1013.
371. Ligresti, A.; Bisogno, T.; Matias, I.; De Petrocellis, L.; Cascio, M. G.; Cosenza, V.; D'Argenio, G.; Scaglione, G.; Bifulco, M.; Sorrentini, I.; Di Marzo, V. Possible Endocannabinoid Control of Colorectal Cancer Growth. Gastroenterology 2003, 125, 677-687.
372. Lichtman, A. H.; Hawkins, E. G.; Griffin, G.; Cravatt, B. F. Pharmacological Activity of Fatty Acid Amides Is Regulated, but Not Mediated, by Fatty Acid Amide Hydrolase in Vivo. J. Pharmacol. Exp. Ther. 2002, 302, 73-79.
373. Tornqvist, H.; Belfrage, P. Purification and Some Properties of a Monoacylglycerol-Hydrolyzing Enzyme of Rat Adipose Tissue. J. Biol. Chem. 1976, 251, 813-819.
374. Sakurada, T.; Noma, A. Subcellular Localization and Some Properties of Monoacylglycerol Lipase in Rat Adipocytes. J. Biochem. (Tokyo) 1991, 90, 1413-1419.
375. Karlsson, M.; Contreras, J. A.; Hellman, U.; Tornqvist, H.; Holm, C. cDNA Cloning, Tissue Distribution, and Identification of the Catalytic Triad of Monoglyceride Lipase. Evolutionary Relationship to Esterases, Lysophospholipases, and Haloperoxidases. J. Biol. Chem. 1997, 272, 27218-27223.
376. Karlsson, M.; Reue, K.; Xia, Y. R.; Lusis, A. J.; Langin, D.; Tornqvist, H.; Holm, C. Exon-Intron Organization and Chromosomal Localization of the Mouse Monoglyceride Lipase Gene. Gene 2001, 272, 11-18.
377. Dinh, T. P.; Carpenter, D.; Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D. Brain Monoglyceride Lipase Participating in Endocannabinoid Inactivation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10819-10824.
378. Erratum: Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13961.
379. Gulyas, A. I.; Cravatt, B. F.; Bracey, M. H.; Dinh, T. P.; Piomelli, D.; Boscia, F.; Freund, T. F. Segregation of Two Endocannabinoid-Hydrolyzing Enzymes into Pre- and Postsynaptic Compartments in the Rat Hippocampus, Cerebellum and Amygdala. Eur. J. Neurosci. 2004, 20, 441-458.
380. Morozov, Y. M.; Ben Ari, Y.; Freund, T. F. The Spatial and Temporal Pattern of Fatty Acid Amide Hydrolase Expression in Rat Hippocampus during Postnatal Development. Eur. J. Neurosci. 2004, 20, 459-466.
381. Dinh, T. P.; Kathuria, S.; Piomelli, D. RNA Interference Suggests a Primary Role for Monoacylglycerol Lipase in the Degradation of the Endocannabinoid 2-Arachidonoylglycerol. Mol. Pharmacol. 2004, 66, 1260-1264.
382. Saario, S. M.; Savinainen, J. R.; Laitinen, J. T.; Järvinen, T.; Niemi, R. Monoglyceride Lipase-like Enzymatic Activity Is Responsible for Hydrolysis of 2-Arachidonoylglycerol in Rat Cerebellar Membranes. Biochem. Pharmacol. 2004, 67, 1381-1387.
383. Walter, L.; Dinh, T.; Stella, N. ATP Induces a Rapid and Pronounced Increase in 2-Arachidonoylglycerol Production by Astrocytes, a Response Limited by Monoacylglycerol Lipase. J. Neurosci. 2004, 24, 8068-8074.
384. Cascio, M. G.; Bisogno, T.; Matias, I.; De Petrocellis, L.; Orlando, P.; Di Marzo, V. Enzymes for 2-AG Biosynthesis and Metabolism in Cell Lines, and Their Pharmacological Inhibitions. 2004 Symposium on the Cannabinoids; International Cannabinoid Research Society: Burlington, VT, 2004; p 110.
385. Hampson, A. J.; Hill, W. A.; Zan, P. M.; Makriyannis, A.; Leung, E.; Eglen, R. M.; Bornheim, L. M. Anandamide Hydroxylation by Brain Lipoxygenase: Metabolite Structures and Potencies at the Cannabinoid Receptor. Biochim. Biophys. Acta 1995, 1259, 173-179.
386. Ueda, N.; Yamamoto, K.; Yamamoto, S.; Tokunaga, T.; Shirakawa, E.; Shinkai, H.; Ogawa, M.; Sato, T.; Kudo, I.; Inoue, K.; Takizawa, H.; Nagan, T.; Hirobe, M.; Matsuki, N.; Saito, H. Lipoxygenase-Catalyzed Oxygenation of Arachidonylethanolamide, a Cannabinoid Receptor Agonist. Biochim. Biophys. Acta 1995, 1254, 127-134.
387. Yu, M.; Ives, D.; Ramesha, C. S. Synthesis of Prostaglandin E-2 Ethanolamide from Anandamide by Cyclooxygenase-2. J. Biol. Chem. 1997, 272, 21181-21186.
388. Edgemond, W. S.; Hillard, C. J.; Falck, J. R.; Kearn, C. S.; Campbell, W. B. Human Platelets and Polymorphonuclear Leukocytes Synthesize Oxygenated Derivatives of Arachidonylethanolamide (Anandamide): Their Affinities for Cannabinoid Receptors and Pathways of Inactivation. Mol. Pharmacol. 1998, 54, 180-188.
389. Kozak, K. R.; Rowlinson, S. W.; Marnett, L. J. Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glyceryl Prostaglandins by Cyclooxygenase-2. J. Biol. Chem. 2000, 275, 33744-33749.
390. Kozak, K. R.; Prusakiewicz, J. J.; Rowlinson, S. W.; Schneider, C.; Marnett, L. J. Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol. J. Biol. Chem. 2001, 276, 30072-30077.
391. Kozak, K. R.; Gupta, R. A.; Moody, J. S.; Ji, C.; Boeglin, W. E.; DuBois, R. N.; Brash, A. R.; Marnett, L. J. 15-Lipoxygenase Metabolism of 2-Arachidonylglycerol. Generation of a Peroxisome Proliferator-Activated Receptor α Agonist. J. Biol. Chem. 2002, 277, 23278-23286.
392. Veldhuis, W. B.; van der Stelt, M.; Wadman, M. W.; van Zadelhoff, G.; Maccarrone, M.; Fezza, F.; Veldink G. A.; Vliegenthart, J. F. G.; Bär, P. R.; Nicolay, K.; Di Marzo, V. Neuroprotection by the Endogenous Cannabinoid Anandamide and Arvanil against in Vivo Excitotoxicity in the Rat: Role of Vanilloid Receptors and Lipoxygenases. J. Neurosci. 2003,23, 4127-4133.
393. Craib, S. J.; Ellington, H. C.; Pertwee, R. G.; Ross, R. A. A Possible Role of Lipoxygenase in the Activation of Vanilloid Receptors by Anandamide in the Guinea-Pig Bronchus. Br. J. Pharmacol. 2001, 134, 30-37.
394. van der Stelt, M.; van Kuik, J. A.; Ban, M.; van Zadelhoff, G.; Leeflang, B. R.; Veldink, G. A.; Finazzi-Agrò, A.; Vliegenthart, J. F. G.; Maccarrone, M. Oxygenated Metabolites of Anandamide and 2-Arachidonoylglycerol: Conformational Analysis and Interaction with Cannabinoid Receptors, Membrane Transporter, and Fatty Acid Amide Hydrolase. J. Med. Chem. 2002, 45, 3709-3720.
395. Weber, A.; Ni, J.; Ling, K. H. J.; Acheampong, A.; Tang-Liu, D. D. S.; Burk, R.; Cravatt, B. F.; Woodward, D. Formation of Prostamides from Anandamide in FAAH Knockout Mice Analyzed by HPLC with Tandem Mass Spectrometry. J. Lipid Res. 2004, 45, 757-763.
396. α in FAAH -/- and FAAH +/+ Mice. 2004 Symposium on the Cannabinoids; International Cannabinoid Research Society: Burlington, VT, 2004; p 78.
397. Kim, J.; Alger, B. E. Inhibition of Cyclooxygenase-2 Potentiates Retrograde Endocannabinoid Effects in Hippocampus. Nat. Neurosci. 2004, 7, 697-708.
398. 2 Cannabinoid Receptors in Rat Brain and Human Tonsils. Adv. Exp. Med. Biol. 1999, 469, 527-533.
399. 2 Ethanolamide. J. Pharmacol. Exp. Ther. 2002, 301, 900-907.
400. Matias, I.; Chen, J.; De Petrocellis, L.; Bisogno, T.; Ligresti, A.; Fezza, F.; Krauss, A. H. P.; Shi, L.; Protzman, C. E.; Li, C.; Liang, Y.; Nieves, A. L.; Kedzie, K. M.; Burk, R. M.; Di Marzo, V.; Woodward, D. F. Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism. J. Pharmacol. Exp. Ther. 2004, 309, 745-757.
401. Stanke-Labesque, F.; Mallaret, M.; Lefebvre, B.; Hardy, G.; Caron, F.; Bessard, G. 2-Arachidonoyl Glycerol Induces Contraction of Isolated Rat Aorta: Role of Cyclooxygenase-Derived Products. Cardiovasc. Res. 2004, 63, 155-160.
402. Rockwell, C. E.; Kaminski, N. E. A Cyclooxygenase Metabolite of Anandamide Causes Inhibition of Interleukin-2 Secretion in Murine Splenocytes. J. Pharmacol. Exp. Ther. 2004, 311, 683-690.
403. Bornheim, L. M.; Kim, K. Y.; Chen, B.; Correia, M. A. Microsomal Cytochrome P450-Mediated Liver and Brain Anandamide Metabolism. Biochem. Pharmacol. 1995, 50, 677-686.
404. Guhring, H.; Hamza, M.; Sergejeva, M.; Ates, M.; Kotalla, C. E.; Ledent, C.; Brune, K. A Role for Endocannabinoids in Indomethacin-Induced Spinal Antinociception. Eur. J. Pharmacol. 2002, 454, 153-163.
405. Ates, M.; Hamza, M.; Seidel, K.; Kotalla, C. E.; Ledent, C.; Guhring, H. Intrathecally Applied Flurbiprofen Produces an Endocannabinoid-Dependent Antinociception in the Rat Formalin Test. Eur. J. Neurosci. 2003, 17, 597-604.
406. Holt, S.; Fowler, C. J. Anandamide Metabolism by Fatty Acid Amide Hydrolase in Intact C6 Glioma Cells. Increased Sensitivity to Inhibition by Ibuprofen and Flurbiprofen upon Reduction of Extra- but Not Intracellular pH. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 367, 237-244.
407. Holt, S.; Nilsson, J.; Omeir, R.; Tiger, G.; Fowler, C. J. Effects of pH on the Inhibition of Fatty Acid Amidohydrolase by Ibuprofen. Br. J. Pharmacol. 2001, 133, 513-520.
408. Fowler, C. J.; Holt, S.; Tiger, G. Acidic Nonsteroidal Anti-Inflammatory Drugs Inhibit Rat Brain Fatty Acid Amide Hydrolase in a pH-Dependent Manner. J. Enzyme Inhib. Med. Chem. 2003, 18, 55-58.
409. Fowler, C. J. Possible Involvement of the Endocannabinoid System in the Actions of Three Clinically Used Drugs. Trends Pharmacol. Sci. 2004, 25, 59-61.
410. Holt, S.; Costa, B.; Fowler, C. J. FAAH Inhibitors and Indomethacin Reduce Carragenan Induced Hind Paw Inflammation in the Mouse-Role of Cannabinoid Receptors. 2004 Symposium on the Cannabinoids; International Cannabinoid Research Society: Burlington, VT, 2004; p 51.
411. Ueda, N.; Yamanaka, K.; Terasawa, Y.; Yamamoto, S. An Acid Amidase Hydrolyzing Anandamide as an Endogenous Ligand for Cannabinoid Receptors. FEBS Lett. 1999, 454, 267-270.
412. Ueda, N.; Yamanaka, K.; Yamamoto, S. Purification and Characterization of an Acid Amidase Selective for N-Palmitoylethanolamine, a Putative Endogenous Anti-Inflammatory Substance. J. Biol. Chem. 2001, 276, 35552-35557.
413. Ueda, N.; Yamanaka, K.; Katayama, K.; Goparaju, S. K.; Suzuki, H.; Yamamoto, S. Alkaline and Acid Amidases Hydrolyzing Anandamide and Other N-Acylethanolamines. World Rev. Nutr. Diet. 2001, 88, 215-222.
414. Tsuboi, K.; Sun, Y. X.; Okamoto, Y.; Araki, N.; Tonai, T.; Ueda, N. Molecular Characterization of N-Acylethanolamine-Hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase. J. Biol. Chem. 2005, 280, 11082-11092.
415. Vandevoorde, S.; Tsuboi, K.; Ueda, N.; Jonsson, K.-O.; Fowler, C. J.; Lambert, D. M. Esters, Retroesters, and a Retroamide of Palmitic Acid: Pool for the First Selective Inhibitors of N-Palmitoylethanolamine Selective Acid Amidase. J. Med. Chem. 2003, 46, 4373-4376.
416. Tsuboi, K.; Hilligsmann, C.; Vandevoorde, S.; Lambert, D. M.; Ueda, N. N-Cyclohexanecarbonylpentadecylamine: A Selective Inhibitor of the Acid Amidase Hydrolysing N-Acylethanolamines, as a Tool To Distinguish Acid Amidase from Fatty Acid Amide Hydrolase. Biochem J. 2004, 379, 99-106.
417. 2 Cannabinoid Receptor Agonists: Pain Relief without Psychoactive Effects? Curr. Opin. Pharmacol. 2003, 3, 62-67.
418. Cravatt, B. F.; Lichtman, A. H. The Endogenous Cannabinoid System and Its Role in Nociceptive Behavior. J. Neurobiol. 2004, 61, 149-160.
419. Baker, D.; Pryce, G.; Giovannoni, G.; Thompson, A. J. The Therapeutic Potential of Cannabis. Lancet Neurol. 2003, 2, 291-298.
420. Bifulco, M.; Di Marzo, V. Targeting the Endocannabinoid System in Cancer Therapy: A Call for Further Research. Nat. Med. 2002, 8, 547-550.
421. Velasco, G.; Galve-Roperh, I.; Sánchez, C.; Blázquez, C.; Guzmán, M. Hypothesis: Cannabinoid Therapy for the Treatment of Gliomas? Neuropharmacology 2004, 47, 315-323.
422. Gaetani, S.; Cuomo, V.; Piomelli, D. Anandamide Hydrolysis: A New Target for Anti-Anxiety Drugs? Trends Mol. Med. 2003, 9, 474-478.
423. Fernández-Ruiz, J. J.; Lastres-Becker, I.; Cabranes, A.; de Lago, E.; Ramos, J. A. Involvement of the Endocannabinoid System in Motor Disorders. Curr. Med. Chem.: Cent. Nerv. Syst. Agents 2004, 4, 175-182.
424. Baker, D.; Pryce, G.; Croxford, J. L.; Brown, P.; Pertwee, R. G.; Makriyannis, A.; Khanolkar, A.; Layward, L.; Fezza, F.; Bisogno, T.; Di Marzo, V. Endocannabinoids Control Spasticity in a Multiple Sclerosis Model. FASEB J. 2001, 15, 300-302.
425. Bifulco, M.; Laezza, C.; Valenti, M.; Ligresti, A.; Portella, G.; Di Marzo, V. A New Strategy To Block Tumor Growth by Inhibiting Endocannabinoid Inactivation. FASEB J. 2004, 18, 1606-1608.
426. van Oosten, B. W.; Killestein, J.; Mathus-Vliegen, E. M. H.; Polman, C. H. Multiple Sclerosis Following Treatment with a Cannabinoid Receptor-1 Antagonist. Mult. Scler. 2004, 10, 330-331.
427. 2 Receptor. J. Pharmacol. Exp. Ther. 2001, 296, 420-425.
428. 1 Cannabinoid Receptor. J. Pharmacol. Exp. Ther. 2003, 306, 363-370.
429. 2 Cannabinoid Receptors. Eur. J. Pharmacol. 2004, 505, 1-9.
430. McFarland, M. J.; Barker, E. L. Anandamide transport. Pharmacol Ther. 2004, 104, 117-135.